This discovery dispute ruling has no material financial impact on TEVA. The underlying antitrust case against Corcept continues. Monitor for summary judgment motions or trial dates, which could affect the stock if material exposure emerges.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 16 $32.22entry
- T+1 · 4mo ago −0.59%α +0.40% · $32.03
- T+5 · 4mo ago −3.23%α −1.56% · $31.18
- T+20 · 3mo ago +13.35%α +9.73% · $36.52
- T+60 · 6w ago +27.56%α +23.59% · $41.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A federal magistrate judge partially granted and partially denied Corcept Therapeutics' motion to compel discovery from Teva's CEO Richard Francis. Teva's CEO must sit for a limited two-hour deposition regarding his critique of Teva's generic mifepristone promotion strategies, but Teva is not required to produce his custodial documents. This is a routine procedural discovery ruling in an ongoing antitrust case with no immediate financial impact.
Court Ruling Details
Key Facts
- Teva is the plaintiff in an antitrust case against Corcept regarding generic mifepristone for Cushing's syndrome.
- Corcept sought to depose Teva's CEO Richard Francis and obtain his documents; the court granted a limited 2-hour deposition on one topic and denied document production.
- The deposition is limited to Mr. Francis's critique of Teva's strategy for promoting generic mifepristone and his ideas for solutions.
- Fact discovery in the case closed on May 15, 2026.
Financial Impact
None stated. The ruling involves only discovery scope, no monetary award or injunctive relief.
Risk Factors
- CEO deposition may reveal internal discussions that could weaken Teva's causation argument in the antitrust case.
- Continued litigation costs and management distraction from the underlying antitrust case.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-10e56aaee5-TEVA |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers